CC-223: Clinical Trials

5 trials of CC-223, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

4 completed, 1 terminated. 5 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	5	Completed 4, Terminated 1
Phase 2	1	Completed 1

Follow CC-223: new trials by email Literature Review of CC-223 trials Research Report on CC-223

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma CC-122, CC-223, Rituximab - Lymphoma, Large B-Cell, Diffuse	Phase 1	Terminated	Celgene	174	2013-12-18	2024-01-18
CC-223 and Ketoconazole Drug-Drug Interaction Study CC-223, Ketoconazole - Healthy Volunteers	Phase 1	Completed	Celgene	14	2013-07-01	2019-11-12
A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects CC-223 - Safety and Pharmacokinetics in Healthy Volunteer Subjects	Phase 1	Completed	Celgene	18	2012-06-01	2019-11-12
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer CC-223, erlotinib, CC-223, oral azacitidine - Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer	Phase 1	Completed	Celgene	76	2012-05-01	2019-11-12
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma CC-223 - Multiple Myeloma, Diffuse Large B-Cell Lymphoma	Phase 1 / Phase 2	Completed	Celgene	226	2010-07-20	2022-12-13

Conditions studied

Sponsors

Countries

Top investigators